Nicholas Hoffman & Company’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.16M | Sell |
48,195
-439
| -0.9% | -$11.5K | 0.02% | 140 |
|
|
2026
Q1 | $1.37M | Hold |
48,634
| – | – | 0.03% | 111 |
|
|
2025
Q4 | $1.21M | Buy |
48,634
+7,195
| +17% | +$181K | 0.03% | 122 |
|
|
2025
Q3 | $1.06M | Buy |
41,439
+603
| +1% | +$14.9K | 0.03% | 134 |
|
|
2025
Q2 | $990K | Buy |
40,836
+39
| +0.1% | +$910 | 0.03% | 130 |
|
|
2025
Q1 | $1.03M | Buy |
40,797
+9,428
| +30% | +$247K | 0.04% | 125 |
|
|
2024
Q4 | $832K | Sell |
31,369
-13,394
| -30% | -$363K | 0.03% | 135 |
|
|
2024
Q3 | $1.3M | Buy |
44,763
+533
| +1% | +$15.5K | 0.05% | 108 |
|
|
2024
Q2 | $1.24M | Buy |
44,230
+2,730
| +7% | +$75.2K | 0.06% | 103 |
|
|
2024
Q1 | $1.15M | Sell |
41,500
-2,711
| -6% | -$75.2K | 0.06% | 109 |
|
|
2023
Q4 | $1.27M | Buy |
44,211
+12,063
| +38% | +$365K | 0.08% | 94 |
|
|
2023
Q3 | $1.07M | Buy |
32,148
+998
| +3% | +$35.3K | 0.08% | 105 |
|
|
2023
Q2 | $1.14M | Sell |
31,150
-83
| -0.3% | -$3.23K | 0.04% | 102 |
|
|
2023
Q1 | $1.27M | Buy |
31,233
+717
| +2% | +$31K | 0.11% | 90 |
|
|
2022
Q4 | $1.56M | Buy |
30,516
+12
| +0% | +$575 | 0.17% | 72 |
|
|
2022
Q3 | $1.33M | Buy |
30,504
+12
| +0% | +$583 | 0.06% | 74 |
|
|
2022
Q2 | $1.6M | Buy |
30,492
+82
| +0.3% | +$4.18K | 0.07% | 63 |
|
|
2022
Q1 | $1.57M | Buy |
30,410
+92
| +0.3% | +$4.77K | 0.06% | 67 |
|
|
2021
Q4 | $1.79M | Buy |
30,318
+1,002
| +3% | +$49.6K | 0.06% | 62 |
|
|
2021
Q3 | $1.26M | Buy |
29,316
+620
| +2% | +$27.5K | 0.22% | 84 |
|
|
2021
Q2 | $1.12M | Buy |
28,696
+3,123
| +12% | +$121K | 0.2% | 94 |
|
|
2021
Q1 | $926K | Sell |
25,573
-5,210
| -17% | -$185K | 0.19% | 108 |
|
|
2020
Q4 | $1.13M | Buy |
30,783
+284
| +0.9% | +$10.4K | 0.26% | 72 |
|
|
2020
Q3 | $1.06M | Buy |
30,499
+6,834
| +29% | +$240K | 0.28% | 67 |
|
|
2020
Q2 | $734K | Sell |
23,665
-3,325
| -12% | -$113K | 0.21% | 92 |
|
|
2020
Q1 | $836K | Sell |
26,990
-6,744
| -20% | -$230K | 0.28% | 78 |
|
|
2019
Q4 | $1.25M | Buy |
33,734
+1,055
| +3% | +$37.6K | 0.35% | 62 |
|
|
2019
Q3 | $1.11M | Buy |
32,679
+6,273
| +24% | +$228K | 0.34% | 65 |
|
|
2019
Q2 | $1.08M | Sell |
26,406
-304
| -1% | -$12.1K | 0.34% | 68 |
|
|
2019
Q1 | $1.08M | Buy |
26,710
+2,044
| +8% | +$81.9K | 0.35% | 69 |
|
|
2018
Q4 | $1.02M | Sell |
24,666
-436
| -2% | -$18.1K | 0.35% | 69 |
|
|
2018
Q3 | $1.05M | Sell |
25,102
-167
| -0.7% | -$6.43K | 0.35% | 66 |
|
|
2018
Q2 | $870K | Buy |
25,269
+3
| +0% | +$103 | 0.32% | 75 |
|
|
2018
Q1 | $851K | Buy |
25,266
+1,821
| +8% | +$62.6K | 0.33% | 78 |
|
|
2017
Q4 | $806K | Buy |
23,445
+2
| +0% | +$68 | 0.32% | 81 |
|
|
2017
Q3 | $794K | Buy |
23,443
+1
| +0% | +$32 | 0.33% | 79 |
|
|
2017
Q2 | $747K | Buy |
23,442
+2
| +0% | +$63 | 0.34% | 77 |
|
|
2017
Q1 | $761K | Sell |
23,440
-737
| -3% | -$23.2K | 0.36% | 73 |
|
|
2016
Q4 | $757K | Buy |
24,177
+2
| +0% | +$61 | 0.38% | 67 |
|
|
2016
Q3 | $777K | Buy |
24,175
+2
| +0% | +$67 | 0.43% | 64 |
|
|
2016
Q2 | $808K | Buy |
+24,173
| New | +$771K | 0.47% | 57 |
|
Other funds holding PFE
Nicholas Hoffman & Company's PFE Position: Q2 2026 in Review
Nicholas Hoffman & Company reduced its Pfizer (PFE) stake by 0.9% in Q2 2026, selling an estimated $11.5K and leaving 48,195 shares worth $1.16M. The position accounts for 0.02% of the portfolio, ranked #140.
Nicholas Hoffman & Company first reported a position in PFE in Q2 2016 and has held it in 41 quarters since. The position peaked at $1.79M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Nicholas Hoffman & Company held 48,195 shares of Pfizer worth $1.16M as of Q2 2026.
- Nicholas Hoffman & Company sold 439 Pfizer shares in Q2 2026, an estimated $11.5K.
- Pfizer made up 0.02% of Nicholas Hoffman & Company's portfolio in Q2 2026, its #140 holding.
- Nicholas Hoffman & Company first reported a position in Pfizer in Q2 2016 and has held it in 41 quarters since.
- Nicholas Hoffman & Company's Pfizer position peaked at $1.79M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Nicholas Hoffman & Company's 13F filing for Q2 2026, filed 4 Aug 2026.